SternAegis Ventures

Menu

 Invest With Us

Issuer Client News

News & Events

InVivo Therapeutics to Present at JMP Securities Annual Life Sciences Conference

InVivo Therapeutics to Present at JMP Securities Annual Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the JMP Securities Annual Life Sciences Conference on Tuesday, June 20, 2017 at 2:00 PM Eastern Time at the St. Regis New York in New York, NY. This is the first time that the Company has been invited to present at the JMP Securities Annual Life Sciences Conference. The conference will include company executives, KOLs, physicians, patients and industry experts discussing a variety of healthcare topics. Mr. Perrin’s presentation will highlight recent updates to the Company’s Neuro-Spinal Scaffold™ program, while providing an overview of the company.

A live webcast will be available at http://wsw.com/webcast/jmp33/nviv and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 minutes before the event to ensure a timely connection.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

InVivo Therapeutics
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com

Source: InVivo Therapeutics

Brokerage and investment advisory products and services, are offered through Aegis Capital Corp, a member of FINRA and SIPC. Insurance products are made available through, ACC General Agency, a licensed insurance agency. For those persons inquiring from states where a specific associate is not currently securities and/or insurance licensed, the associate will not transact business in that state or provide follow-up individual responses, until after the associate obtains the appropriate registration in the applicable state.

The information provided should not be relied upon in isolation for the purpose of making an investment decision. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. Prior to making any investment or financial decision, an investor should seek advice from a financial, legal, tax and other professional that consider all of the particular facts and circumstances of an investor's situation. The opinions expressed and material provided are for information purposes only and is not an offer, recommendation, or solicitation of any product, strategy or transaction. Any views, strategies or products discussed may not be appropriate or suitable for all individuals and are subject to risks.

Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Check the background of your financial professional on FINRA's BrokerCheck

Form CRS and General Disclosures

Aegis Risk Disclosures